Kornimate/medical-research-clean huggingface dataset:
prospective observational study on plerixafor after chemotherapy

Conditions: Lymphoma; Myeloma

Summary: plerixafor is a new cxcr4 inhibitor that is able to improve peripheral blood stem cell (pbsc) mobilization when combined with granulocyte-colony-stimulating factor (g-csf). the 'on demand' use of plerixafor at the hematopoietic recovery after chemotherapy + g-csf may be more efficient and cost-effective, but the timing of administration and criteria for patient selection are still under investigation. we collected the data of lymphoma and myeloma patients treated with plerixafor at the hematopoietic recovery after chemotherapy + g-csf. the decision of adding plerixafor was based on pb cd34+ cells at the time of hematopoietic recovery after chemotherapy in patients at their first or subsequent attempt, according to the attending physician choice. the primary endpoint was the assessment of the rate of patients who were able to collect \>=2 x 10\^6 cd34+/kg.

plerixafor is a new cxcr4 inhibitor that is able to improve peripheral blood stem cell (pbsc) mobilization when combined with granulocyte-colony-stimulating factor (g-csf). the 'on demand' use of plerixafor at the hematopoietic recovery after chemotherapy + g-csf may be more efficient and cost-effective, but the timing of administration and criteria for patient selection are still under investigation. we collected the data of lymphoma and myeloma patients treated with plerixafor at the hematopoietic recovery after chemotherapy + g-csf. the decision of adding plerixafor was based on pb cd34+ cells at the time of hematopoietic recovery after chemotherapy in patients at their first or subsequent attempt, according to the attending physician choice. the primary endpoint was the assessment of the rate of patients who were able to collect \>=2 x 10\^6 cd34+/kg. secondary endpoint was the assessment of the rate of patients collecting \> 4 x 10\^6 cd34+/kg and the median number of apheresis to reach the target.

Eligibility criteria:
inclusion criteria: * lymphoma and myeloma patients treated with plerixafor at the hematopoietic recovery after chemotherapy and g-csf exclusion criteria: * patients treated only with g-csf and plerixafor without chemotherapy
abdominal binder to treat orthostatic hypotension (oh) in parkinson's disease (pd)

Conditions: Parkinson's Disease; Neurogenic Orthostatic Hypotension in Parkinson's Disease

Summary: the purpose of the present study is to determine whether the use of an abdominal binder is effective in the non-pharmacological management of orthostatic hypotension in patients suffering from parkinson's disease

in the present single blinded cross-over trial we investigated the effects of an elastic abdominal binder on blood pressure changes (systolic, diastolic and mean blood pressure) after 3 minutes of head-up tilt test in patients with parkinson's disease and orthostatic hypotension. secondarily, we investigated the effects of an elastic abdominal binder on symptoms of orthostatic hypotension in daily living in a 4-weeks open-label follow-up.

Eligibility criteria:
inclusion criteria: * idiopathic pd * hoehn \& yahr stadium \< or = 4 * age: 40-90 * laboratory confirmed neurogenic orthostatic hypotension (noh) * stable pharmacological therapy in the last 6 weeks * full legal competence exclusion criteria: * other major neurologic or psychiatric diseases * untreated diabetes mellitus with clinical features of peripheral neuropathy * major cardiac diseases (ischemic, structural, arrhythmias) * evidence of varices (venous insufficiency stage \> or = c2, "varicose veins") * known or suspected pregnancy * breast feeding
a study examining long response in lung cancer patients treated with tarceva (erlotinib)

Conditions: Non-Small Cell Lung Cancer

Summary: this multicenter, retrospective and prospective observational, cohort study will examine the effect of second-line tarceva treatment on long response in non-small cell lung cancer (nsclc) participants with wild type or unknown egfr status. participants will be observed from the start of treatment for 8 months or until death. the extension of the retrospective versus prospective observation will depend on the lag between the date of the participant enrollment and the date of beginning of erlotinib therapy.


Eligibility criteria:
inclusion criteria: * participants with stage iiib or iv nsclc * participants aged \>/= 18 years * second-line treatment with tarceva started before study inclusion and sd response, or cr/pr according to recist v1.1, lasting for at least 4 weeks exclusion criteria: * known presence of epidermal growth factor receptor (egfr) mutation * participation in a clinical trial with tarceva during the study observation period
study to evaluate the need of needle change for application of intramuscular, subcutaneous and intradermal injection.

Conditions: Knowledge, Attitudes, Practice; Injection Site Reactions

Summary: comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; comparing bruise formation following administration of insulin subcutaneous injections between rfs and the conventional technique. method study site a clinical trial was conducted in two medical-surgical units in a hospital in the period from june 15th to november 30th, 2009, after approval by the ethics and research committee. intervention in a group of patients the investigators used syringes with retractable fixed needle to administer subcutaneous and intramuscular injections. in the group of control, the investigators used the standard technique to administer medications. population of study patients were sequentially enrolled through a lottery system of exposure using random numbers kept in sealed, opaque envelopes. sampling design and sample size subcutaneous injection the sample size was based on the expected proportion of bruising following the injection. it was expected that 40% of patients would show bruising with the conventional technique and 20% with the technique under study for subcutaneous applications. with an alpha error of 5% (p = 0.05) and power of study of 80% (beta error of 20% or 0.2) 240 patients were included, 120 in each group. intramuscular injection the sample size was based on the proportion of patients with moderate to severe pain. it was considered normal the incidence of moderate to severe pain in 30% with a needle exchange, whereas it was considered an increase of up to 40% with the retractable fixed needle. the investigators included 500 patients in each group.


Eligibility criteria:
inclusion criteria: * the investigators included all patients over 18 who agreed to participate in the study for subcutaneous and intramuscular injections. the monitoring was done after the reading, comprehension check, and signing of the term of free consent and clarification. exclusion criteria: * the investigators excluded patients taking anticoagulants or those who had coagulation disorders, injuries, or skin changes.

Keywords: accident prevention blood-borne pathogens protective devices. needlestick injuries injections subcutaneous injections intradermal
eating and physical activity patterns of the population working in the uruguayan state electrical company.

Conditions: Diet Habit; Weight, Body

Summary: stuydy of eatin and physical activity patterns in uruguayan workers and association with obesity, overweight, and tasks.

a sample of workers from the electrical company will be studies as to eating and physical activity patterns, weight variations, and assigned tasks.

Eligibility criteria:
inclusion criteria: * it will include all the officials who joined the company from january 1, 2010 to december 31, 2017, of whom they are between 18 and 65 years old, and the total was from 1964. exclusion criteria: * on the other hand, regarding the officials who meet the inclusion criteria, the following exclusion criteria are established. therefore, those officials who: * do not have a medical check-up at admission and at least one checkup between one year and two years after entering the company * officials who no longer continue to work at the institution at the date of the study. * participants who do not have weight and height recorded in the medical record

Keywords: diet work related physical activity
increasing adherence to lung cancer screening

Conditions: Lung Cancer; Adherence, Patient

Summary: investigators are conducting a pragmatic randomized trial testing the effectiveness of patient and clinician nudge strategies on adherence to lung cancer screening (lcs) \& diagnostic follow-up across eligible primary care clinicians \& patients. following the trial, a subsample of patients \& clinicians will be invited to one-time semi-structured interview \& survey to identify individual \& system-level factors that may restrict or enhance the impact of strategies.

investigators will conduct a pragmatic clinical trial with a 2 x 2 factorial design with clinicians that provide care to screening-eligible patients who are overdue for annual screening or diagnostic evaluation. the specific nudge strategies to be tested are: 1) gain-framed messaging delivered via text messaging to prompt patient adherence to lcs guidelines (patient nudges); and 2) electronic health record (ehr) prompts alerting clinicians when their patients are due for annual screening or diagnostic follow-up (clinician nudges). the rationale for this study is that changing external stimuli to encourage adherence to evidence-based lcs guidelines will increase early detection of lung cancer by removing individual and system-level barriers to identifying and prompting patients who are due for care. the central hypothesis is that the combination of patient and clinician strategies will have the greatest effect on increasing adherence because it will target multilevel determinants of lung cancer screening identified in our prior research including limited screening knowledge and suboptimal ehr design. the proposed strategies are designed to support equitable implementation across diverse settings and populations.

Eligibility criteria:
inclusion criteria: clinicians will be eligible if they: 1. are practicing primary care or specialty care physicians at a recruiting site within the university of pennsylvania health system; 2. care for patients who completed lcs via ldct in 2019-2023; and 3. do not opt-out of study participation. patients will be eligible if they: 1. are eligible for lcs based on 2021 us preventive services task force (uspstf) population guidelines (aged 50-80; smoking history of 20-pack years; smoked within the last 15 years) 2. completed lcs via ldct in 2019-2023; 3. have not been diagnosed with lung cancer; 4. meet criteria for non-adherence; 5. remain eligible for lcs during the trial enrollment period; and 6. receive lcs care from a clinician that has not opted-out of study participation exclusion criteria: patients will be excluded if they: a) have a highly suspicious baseline ldct (lung-rads 4b/x) given the presence of existing clinical pathways to ensure adherence in this group

Keywords: screening nudge adherence implementation science behavioral science digital health
a study of nasopharyngeal carcinoma (npc) treated with celecoxib and zd1839

Conditions: Nasopharyngeal Carcinoma

Summary: egfr and cox-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in npc.cox-2 and egfr inhibitors are active in npc.there is synergistic action between cox-2 and egfr inhibitors. study hypothesis: celecoxib and gefitinib can reduce angiogenesis and induce anti-tumorigenicity in patients with nasopharngeal cancer.


Eligibility criteria:
inclusion criteria: 1. histologically proven npc. 2. any clinical stage npc as defined by the ajcc/uicc system. 3. no prior radiotherapy, chemoradiotherapy, immunotherapy or investigational agents. 4. no prior nsaids or corticosteroids for at least 4 weeks. 5. ecog performance status ≤ 2. 6. adequate end organ function 7. life expectancy \> 3 months. 8. signed informed consent - exclusion criteria: 1. inability to take celecoxib and gefitinib for the specified period of time (14 days) prior to definitive therapy. 2. tumor not visible on fibre nasopharyngoscopy for biopsy. 3. known peptic ulcer disease. 4. evidence of clinically active interstitial lung disease. 5. previous or concomitant malignancies with the exception of adequately treated carcinoma-in-situ of the cervix and basal or squamous cell carcinoma of the skin. 6. women who are pregnant or lactating. females with child-bearing potential must have a negative serum pregnancy test within 7 days prior to study enrolment. 7. women of childbearing potential who are not practising adequate contraception. 8. concurrent medical problems that would significantly limit compliance with the study. 9. presence of any underlying medical conditions (eg. unstable or uncompensated respiratory, cardiac, renal or hepatic disease) that in the opinion of the investigator would make the patient unsuitable for study participation. 10. known hypersensitivity to celecoxib and gefitinib or any of the excipients of the products, known sulphonamide sensitivity and allergic reaction following the ingestion of nsaids. 11. known hiv, hbv or hcv infection. -

Keywords: celecoxib, npc, gefitinib
exercise induced plasma volume expansion lowers cardiovascular strain

Conditions: Cardiac Output; Stroke Volume

Summary: the goal of this observational study was to better understand the impact of increased plasma volume on later exercise in hypoxia. investigators examined young, healthy, males who regularly participated in aerobic exercise. investigators first measured participant's response to exercise in hypoxia (simulated \~7,500 feet above sea level). the investigators then had participants either 1) undergo 1 bout of high intensity interval exercise or 2) undergo 1 bout of moderate, continuous exercise. 48 hours after the exercise, participants were again examined in hypoxia.

a crossover design was utilized to assess the effects of exercise-induced plasma volume expansion on cycling performance in hypoxia. all participants completed a high intensity (hi) bout and control (con) intervention in a counterbalanced order. the hi bout consisted of 8x4min cycling bouts at 85% of vo2peak with 4 min rest between intervals. con consisted of cycling at 50% vo2peak. two 15 km, self-paced cycling time trials (tt) were performed before and after each training intervention. the first tt occurred 5 days before the training intervention (hi or con) and the second tt occurred 48 hours post intervention. interventions were separated by 14 days to ensure sufficient washout of any training effect as data have suggested retention of expanded plasma volume may last for 7-14 days. during washout, participants were instructed to continue their normal exercise routine. the investigators hypothesized that a single hi session would increase plasma volume and attenuate cardiovascular strain during exercise in hypoxia, as evidenced by reductions in hr and elevations in sv and q. furthermore, the investigators hypothesized that these changes would contribute to a reduced time-to-completion in a 15 km, self-paced cycling tt.

Eligibility criteria:
inclusion criteria: * males age 18-38 * exercise at least 3 times/week for at least 30 minutes/day for the past 3 months. exclusion criteria: * frequent hot bath or sauna users * resided at altitude greater than 2,500 meters for \>14 days. * cardiovascular or metabolic disease

Keywords: hypervolemia high intensity exercise altitude exposure
accumulative effects of talus mobilization

Conditions: Ankle Sprains; Ankle Fractures; Ankle Dislocations; Ankle Bruises; Achilles Tendon Rupture

Summary: the purpose of this study is to verify the effect of anteroposterior talus mobilization on range of motion, pain, and functional capacity in participants with sub-acute and chronic ankle injuries.

the purpose of this study was to verify the acute effect (one session) and chronic (six sessions) and follow-up of the anteroposterior talus mobilization maitland's grade iii on range of motion, pain, and functional capacity in participants with sub-acute and chronic ankle injuries. thirty eight volunteers subjects (male and female) participated of this study with minimum 18 and maximum 59 years old. the volunteers were allocated in two groups: experimental and control. the variables related to range of motion, pain and functional capacity were measured by biplane goniometer, visual analog scale and foot and ankle ability measure respectively in four moments: 1- baseline; 2- after the first intervention; 3- after the sixth intervention (two weeks); 4- follow-up (one month). the experimental group received anteroposterior articular mobilization of the talus and the control group received manual contact.

Eligibility criteria:
inclusion criteria: * unilateral traumatic injury of the ankle with at least two weeks and maximum eight months * at least a 5º limitation of passive dorsiflexion in comparison to the contralateral side * do not be under another physical therapy treatment for the lesion * able to unload partial or total body weight * do not be in use of analgesic * provided informed consent after receiving and explanation of all procedures and pertinent information regarding the study exclusion criteria: * joint blockage by surgical fixation or ankylosis * presence of vascular, rheumatic, neurological and neoplastic disease in the lower limb * open or contagious lesion in the ankle region * pain during palpation in the region anterior of the ankle

Keywords: mobilization joint range of motion ankle manual therapy
efficacy and safety of fsh-gex™ in comparison with 150 iu gonal-f®

Conditions: Infertility

Summary: the aim of the current study was the determination of the recommended standard treatment dose of fsh-gex(tm) in women undergoing intracytoplasmic sperm injection (icsi) treatment as assessed by follicle growth.

this was a phase ii, randomized, assessor-blind, comparator-controlled, multiple dose study in women undergoing icsi treatment. the primary objective of the study was the determination of the recommended standard treatment dose of fsh-gex™ as assessed by follicle growth dynamics in women between 18 and 37 years of age who were undergoing intracytoplasmic sperm injection treatment.

Eligibility criteria:
inclusion criteria: * female patient for whom icsi treatment is justified * serum follicle-stimulating hormone concentration * anti-mullerian hormone concentration * antral follicle count * body mass index and body weight * presence of both ovaries * regular spontaneous cycles between 21 and 35 days in length * normal uterine cavity as assessed by transvaginal sonography at screening * willing and able to comply with the protocol * willing and able to provide written informed consent exclusion criteria: * patients who had more than two unsuccessful previous assisted reproduction technology cycles before inclusion into the study * previous poor responders * patients with previous hyperstimulation syndrome or cycle cancellation because of imminent hyperstimulation syndrome * patients with a history of or current polycystic ovarian morphology syndrome * patients with a history of or current endometriosis iii or iv * presence of ovarian cyst at screening * any contraindication to becoming pregnant * history of ≥ 3 clinical or preclinical miscarriages * abnormal cervical smear, papanicolaou \[pap\] score ≥ 3 * any history of malignant cancer other than in situ breast or skin cancer requiring local excision * any endocrine abnormalities requiring treatment * any clinically significant systematic disease * any known infection with human immunodeficiency virus, hepatitis b or c * history of thrombosis or other risk factors including any coagulation abnormality leading to an increased risk of clotting * family history of genetic risk factors concerning pregnancy or birth * use of concomitant medication, which in the opinion of the investigator might interfere with icsi preparation procedures * active smoking * any active substance abuse of drugs, medications or alcohol within the last five years * patients in an institution by official or court order * patients who are unable or unwilling to provide informed consent * any participation in another clinical trial within the last 60 days before randomisation * previous fsh-gex™ administration. * known hypersensitivity to any component of the investigational and non investigational products used in this study

Keywords: in-vitro fertilization reproductive disorder
fasting mimicking diet program to improve chemotherapy in hormone receptor postive (hr+), her2- breast cancer

Conditions: Fasting Mimicking Diet; HER2-negative Breast Cancer; Hormone Receptor-positive Breast Cancer; Pathological Complete Response; Objective Response Rate; Neoadjuvant Chemotherapy

Summary: in preclinical research, short-term fasting (stf) protects tumor-bearing mice against the toxic effects of chemotherapy, improves the cd8+ effector t-cell intratumor infiltration, while enhancing the chemotherapy efficacy. short-term use of a "fasting-mimicking diet" (fmd) caused a major increase in the efficacy of cancer treatment in mice comparable to stf. in humans, the investigators recently performed a multicenter randomized phase ii trial showing that patients with human epidermal growth factor receptor 2 (her2) negative breast cancer treated with neoadjuvant chemotherapy and fmd displayed a better radiological response and a better pathological response (90-100% vs \<90% tumor cell reduction) than patients treated with chemotherapy without fmd (de groot, nat commun 2020; nct02126449). therefore these findings will be validated in a phase 3 trial with the underlying hypothesis that fmd during neoadjuvant chemotherapy for breast cancer improves clinical outcomes, potentially due to improved local immunity.

stf during neadjuvant chemotherapy aiming to improve the chemotherapy efficacy and decline the side effects in patients with stage ii-iii hr+, her2- breast cancer

Eligibility criteria:
inclusion criteria: * clinical stage ii-iii (ct1cn+ or ≥t2 any cn, cm0), hr+, her2- breast cancer * detectable and measurable disease (breast and/or lymph nodes) * world health organization (who) performance status 0-2 * adequate organ function assessed by standard pre-treatment assessment: * adequate bone marrow function: white blood cells (wbcs) ≥3.0 x 109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l * adequate liver function: bilirubin ≤1.5 x upper limit of normal (unl) range, alat and/or asat ≤2.5 x unl, alkaline phosphatase ≤5 x unl * adequate renal function: the calculated creatinine clearance should be ≥50 ml/min * available for treatment and follow-up * written informed-consent * willing to fill in quality of life and cognition questionnaires * ability to read and understand dutch language, accessibility to a computer with internet connection and independent use of computer exclusion criteria: * patient history of invasive or ipsilateral non-invasive breast cancer * active malignancy in the last 5 years, with the exclusion of basal cell carcinoma or pre-invasive cervical neoplasia/dysplasia. * body mass index (bmi) \< 18.5 kg/m2 * pregnancy or lactating * food allergy for ingredients of fmd (nuts, soy, honey) * a metabolic condition affecting gluconeogenesis or adaptation to periodic fasting. (diabetes mellitus for example)